New hope for ALS patients: experimental drug aims to preserve muscle function
NCT ID NCT04057898
Summary
This clinical trial is testing whether an experimental drug called MN-166 (ibudilast) can slow the progression of ALS (amyotrophic lateral sclerosis or Lou Gehrig's disease). The study involves 234 adults recently diagnosed with ALS, who will take either the drug or a placebo for 12 months to see if it helps maintain their physical abilities and strength. The main goal is to see if the drug can slow the decline in daily function and potentially extend survival time for people living with this condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Augusta University
Augusta, Georgia, 30912, United States
-
Duke University
Durham, North Carolina, 27705, United States
-
Hennepin Healthcare Research Institute
Minneapolis, Minnesota, 55415, United States
-
Hopital de L'Enfant-Jesus, CHU de Quebec-Universite Laval
Québec, G1J 1Z4, Canada
-
Indiana University IU Health Neuroscience Center
Indianapolis, Indiana, 46202, United States
-
Johns Hopkins University
Baltimore, Maryland, 21287, United States
-
Lehigh Valley Health Network
Allentown, Pennsylvania, 18103, United States
-
Mayo Clinic
Jacksonville, Florida, 32224, United States
-
McMaster University Medical Center
Hamilton, Ontario, L8N 3Z5, Canada
-
Montreal Neurological Institute and Hospital
Montreal, Quebec, H3A 2B4, Canada
-
SUNY Upstate Medical University
Syracuse, New York, 13210, United States
-
Sunnybrook Research Institute
Toronto, Ontario, M4N 3M5, Canada
-
University of Alberta Hospital
Edmonton, Alberta, T6G 2G3, Canada
-
University of California
Orange, California, 92868, United States
-
University of Saskatchewan - Sastakoon Hospital
Saskatoon, Saskatchwean, S7K 0M7, Canada
-
University of Virginia Health System
Charlottesville, Virginia, 22908, United States
Conditions
Explore the condition pages connected to this study.